https://www.pharmaradar360.com/article/pharma-pulse-vicapsys-stateline-merger-and-veritiv-s-tempsafe-rxshield-741f22ac71864ee7PharmaRadar360en2026-09-24T15:59:27.000ZPharma Pulse: Vicapsys-Stateline Merger and Veritiv's TempSafe RxShieldhttps://www.pharmaradar360.com/article/xlv-vs-ibb-how-healthcare-diversification-compares-to-biotech-concentration-4b45fd335a5f66c4PharmaRadar360en2026-09-24T15:57:53.000ZXLV vs IBB: How Healthcare Diversification Compares to Biotech Concentrationhttps://www.pharmaradar360.com/article/erlc-calls-for-stronger-fda-protections-on-mifepristone-58d8b71863d1edc6PharmaRadar360en2026-09-24T15:57:17.000ZERLC Calls for Stronger FDA Protections on Mifepristonehttps://www.pharmaradar360.com/article/taro-pharmaceutical-industries-stock-faces-a-legal-settlement-b82bcea56e890817PharmaRadar360en2026-09-24T15:47:20.000ZTaro Pharmaceutical Industries stock faces a legal settlementhttps://www.pharmaradar360.com/article/decision-orphan-registered-medicinal-products-99fb5dd11a1ac4aaPharmaRadar360en2026-09-24T15:45:45.000ZDecision: Orphan registered medicinal productshttps://www.pharmaradar360.com/article/what-eli-lilly-s-psychedelic-investment-could-mean-for-the-emerging-field-1631e12377162d46PharmaRadar360en2026-09-24T15:37:34.000ZWhat Eli Lilly’s psychedelic investment could mean for the emerging fieldhttps://www.pharmaradar360.com/article/kobayashi-pharmaceutical-receives-take-private-proposal-from-japan-uk-fund-conso-cf4425fbc6c8fdc0PharmaRadar360en2026-09-24T15:35:00.000ZKobayashi Pharmaceutical Receives Take-Private Proposal from Japan-UK Fund Consortium; Deal Could Reach ¥500 Billionhttps://www.pharmaradar360.com/article/atyr-pharma-aligns-with-fda-on-phase-3-trial-design-for-sarcoidosis-drug-efzofit-7e1f399d800d3373PharmaRadar360en2026-09-24T15:29:03.000ZaTyr Pharma aligns with FDA on Phase 3 trial design for sarcoidosis drug efzofitimodhttps://www.pharmaradar360.com/article/fidelity-healthcare-etf-fhlc-vs-vaneck-biotech-etf-bbh-which-fund-is-the-better-36084fc467c759f7PharmaRadar360en2026-09-24T15:10:54.000ZFidelity Healthcare ETF (FHLC) vs. VanEck Biotech ETF (BBH): Which Fund Is the Better Buy?https://www.pharmaradar360.com/article/marinomed-biotech-ag-mari-operations-ordered-closed-f5cdc1e3765a0c59PharmaRadar360en2026-09-24T15:08:05.000ZMarinomed Biotech AG (MARI) Operations Ordered Closedhttps://www.pharmaradar360.com/article/sourcing-the-next-blockbuster-big-pharma-banks-on-chinese-biotech-1b18adbe7944c5f1PharmaRadar360en2026-09-24T15:06:56.000ZSourcing the Next Blockbuster: Big Pharma Banks on Chinese Biotechhttps://www.pharmaradar360.com/article/1-900-bottles-of-thyroid-pills-trigger-fda-s-top-alert-fc4b286a0c33caebPharmaRadar360en2026-09-24T15:03:02.000Z1,900 bottles of thyroid pills trigger FDA’s top alerthttps://www.pharmaradar360.com/article/pro-life-groups-ask-fda-to-restore-abortion-pill-safeguards-704a0ff085fc32d2PharmaRadar360en2026-09-24T15:01:58.000ZPro-Life Groups Ask FDA To Restore Abortion Pill Safeguardshttps://www.pharmaradar360.com/article/cspc-pharmaceutical-says-phase-iii-trial-of-becotatug-achieves-positive-topline-45ba1ec5b8d7169fPharmaRadar360en2026-09-24T15:01:56.000ZCSPC Pharmaceutical Says Phase III Trial Of Becotatug Achieves Positive Topline Resultshttps://www.pharmaradar360.com/article/dhsc-senior-officials-business-expenses-hospitality-and-meetings-april-to-june-2-7d9da5047a679d1ePharmaRadar360en2026-09-24T15:00:06.000ZDHSC: senior officials’ business expenses, hospitality and meetings, April to June 2026https://www.pharmaradar360.com/article/dhsc-senior-officials-business-expenses-hospitality-and-meetings-a328912eb87631b3PharmaRadar360en2026-09-24T15:00:06.000ZDHSC: senior officials’ business expenses, hospitality and meetingshttps://www.pharmaradar360.com/article/dhsc-special-advisers-gifts-hospitality-and-meetings-april-to-june-2026-3dd02564ad41de97PharmaRadar360en2026-09-24T15:00:05.000ZDHSC: special advisers' gifts, hospitality and meetings, April to June 2026https://www.pharmaradar360.com/article/dhsc-special-advisers-gifts-hospitality-and-meetings-52d34624ad3609c5PharmaRadar360en2026-09-24T15:00:05.000ZDHSC: special advisers' gifts, hospitality and meetingshttps://www.pharmaradar360.com/article/dhsc-ministerial-gifts-hospitality-overseas-travel-and-meetings-2332d5d2f3822f2ePharmaRadar360en2026-09-24T15:00:05.000ZDHSC: ministerial gifts, hospitality, overseas travel and meetingshttps://www.pharmaradar360.com/article/dhsc-ministerial-travel-and-meetings-april-to-june-2026-99b9b0a66353fa3ePharmaRadar360en2026-09-24T15:00:04.000ZDHSC: ministerial travel and meetings, April to June 2026https://www.pharmaradar360.com/article/dhsc-business-appointment-rules-advice-april-to-june-2026-6e8c1aef13dcf8a5PharmaRadar360en2026-09-24T15:00:02.000ZDHSC: business appointment rules advice, April to June 2026https://www.pharmaradar360.com/article/dhsc-business-appointment-rules-advice-3b5125a476d37863PharmaRadar360en2026-09-24T15:00:02.000ZDHSC: business appointment rules advicehttps://www.pharmaradar360.com/article/dr-heidi-overton-appears-before-senate-committee-for-confirmation-hearing-as-nex-927f5ad766e1ef04PharmaRadar360en2026-09-24T14:53:43.000ZDr. Heidi Overton appears before Senate committee for confirmation hearing as next FDA commissionerhttps://www.pharmaradar360.com/article/fidelity-healthcare-etf-fhlc-vs-vaneck-biotech-etf-bbh-which-fund-is-the-better-79716d464d0ab893PharmaRadar360en2026-09-24T14:45:36.000ZFidelity Healthcare ETF (FHLC) vs. VanEck Biotech ETF (BBH): Which Fund Is the Better Buy?https://www.pharmaradar360.com/article/pharmaceutical-policy-in-motion-continued-the-trump-administration-s-second-wave-9ef8298908d47403PharmaRadar360en2026-09-24T14:36:03.000ZPharmaceutical Policy in Motion Continued: The Trump Administration’s Second Wave of Drug Pricing Dealshttps://www.pharmaradar360.com/article/high-consequence-infectious-disease-country-specific-risk-11ed7e663ad962cePharmaRadar360en2026-09-24T14:30:06.000ZHigh consequence infectious disease: country specific riskhttps://www.pharmaradar360.com/article/ebola-and-marburg-haemorrhagic-fevers-outbreaks-and-case-locations-16b29cdb0bb31831PharmaRadar360en2026-09-24T14:30:06.000ZEbola and Marburg haemorrhagic fevers: outbreaks and case locationshttps://www.pharmaradar360.com/article/outbreaks-under-monitoring-in-2026-eb6ae222898106b1PharmaRadar360en2026-09-24T14:30:06.000ZOutbreaks under monitoring in 2026https://www.pharmaradar360.com/article/7-breast-cancer-clinical-trials-currently-enrolling-in-the-us-cec940f5bea5ba71PharmaRadar360en2026-09-24T14:28:51.000Z7 Breast Cancer Clinical Trials Currently Enrolling in the UShttps://www.pharmaradar360.com/article/vaccine-update-30d4e36f5ec7eb5aPharmaRadar360en2026-09-24T14:26:02.000ZVaccine updatehttps://www.pharmaradar360.com/article/why-ai-agents-need-regulatory-guardrails-5c84bf499aa76f81PharmaRadar360en2026-09-24T14:17:19.000ZWhy AI Agents Need Regulatory Guardrailshttps://www.pharmaradar360.com/article/watch-live-senators-question-heidi-overton-in-confirmation-hearing-for-fda-commi-1cdb413fdff776b1PharmaRadar360en2026-09-24T14:06:11.000ZWATCH LIVE: Senators question Heidi Overton in confirmation hearing for FDA commissionerhttps://www.pharmaradar360.com/article/pharmaceutical-market-europe-september-2026-4bdbac2b14a27119PharmaRadar360en2026-09-24T14:05:41.000ZPharmaceutical Market Europe – September 2026https://www.pharmaradar360.com/article/china-s-henlius-carves-out-440m-t-cell-engager-deal-with-amberstone-228b047b6c3cadb1PharmaRadar360en2026-09-24T14:02:29.000ZChina’s Henlius carves out $440M T-cell engager deal with Amberstonehttps://www.pharmaradar360.com/article/why-biotech-has-a-lot-riding-on-trump-s-fda-pick-7b6780f9008f70f9PharmaRadar360en2026-09-24T13:58:34.000ZWhy biotech has a lot riding on Trump's FDA pickhttps://www.pharmaradar360.com/article/kyverna-s-cell-therapy-shows-lasting-autoimmune-benefit-2450aa478dccce91PharmaRadar360en2026-09-24T13:54:42.000ZKyverna’s cell therapy shows lasting autoimmune benefithttps://www.pharmaradar360.com/article/acadia-misses-mark-in-alzheimer-s-but-concludes-phase-3-absolutely-worth-pursuin-182796a9f2f9775ePharmaRadar360en2026-09-24T13:46:06.000ZAcadia misses mark in Alzheimer’s but concludes phase 3 ‘absolutely worth’ pursuinghttps://www.pharmaradar360.com/article/panel-will-weigh-overton-s-fda-public-health-direction-e565fb64fbc05ab4PharmaRadar360en2026-09-24T13:42:52.000ZPanel Will Weigh Overton’s FDA Public-Health Directionhttps://www.pharmaradar360.com/article/otsuka-jv-recalls-one-lot-of-sodium-chloride-over-labeling-issue-efc8c0c36d286f61PharmaRadar360en2026-09-24T13:41:53.000ZOtsuka JV recalls one lot of sodium chloride over labeling issuehttps://www.pharmaradar360.com/article/5-things-to-know-in-life-sciences-week-of-sept-21-2026-06f05da46e262ef6PharmaRadar360en2026-09-24T13:32:55.000Z5 things to know in life sciences: Week of Sept. 21, 2026https://www.pharmaradar360.com/article/non-animal-safety-tests-gain-a-new-place-in-fda-drug-rules-but-animal-studies-ar-30132ac08a5c623aPharmaRadar360en2026-09-24T13:31:34.000ZNon-Animal Safety Tests Gain a New Place in FDA Drug Rules, but Animal Studies Are Not Bannedhttps://www.pharmaradar360.com/article/students-take-first-steps-toward-biotech-careers-5ccf576365171d58PharmaRadar360en2026-09-24T13:25:22.000ZStudents Take First Steps Toward Biotech Careershttps://www.pharmaradar360.com/article/organisation-testing-registration-record-of-combo-rapid-lfd-test-users-b084323e6e76370dPharmaRadar360en2026-09-24T13:17:05.000ZOrganisation testing registration: record of combo rapid LFD test usershttps://www.pharmaradar360.com/article/combined-covid-19-and-flu-tests-use-in-ari-outbreaks-in-adult-social-care-homes-81119bdf4cea369aPharmaRadar360en2026-09-24T13:14:45.000ZCombined COVID-19 and flu tests: use in ARI outbreaks in adult social care homeshttps://www.pharmaradar360.com/article/australia-starts-investigation-into-openai-medicare-breach-a86a3687e693513cPharmaRadar360en2026-09-24T13:10:20.000ZAustralia starts investigation into OpenAI Medicare breachhttps://www.pharmaradar360.com/article/pro-life-leaders-call-on-fda-to-restore-abortion-drug-safeguards-d8f96c48f0333a28PharmaRadar360en2026-09-24T13:07:30.000ZPro-Life Leaders Call on FDA to Restore Abortion Drug Safeguardshttps://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-27-september-2026-c943810d2c68d2caPharmaRadar360en2026-09-24T13:05:26.000ZWeekly all-cause mortality surveillance: week ending 27 September 2026https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-2026-to-2027-46b78a2386536090PharmaRadar360en2026-09-24T13:00:03.000ZWeekly all-cause mortality surveillance: 2026 to 2027https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-reports-2026-to-2027-season-32f74fa23fd23c69PharmaRadar360en2026-09-24T13:00:03.000ZNational flu and COVID-19 surveillance reports: 2026 to 2027 seasonhttps://www.pharmaradar360.com/article/syndromic-surveillance-weekly-summaries-for-2026-45747e3878253defPharmaRadar360en2026-09-24T13:00:03.000ZSyndromic surveillance: weekly summaries for 2026https://www.pharmaradar360.com/article/remote-health-advice-weekly-bulletins-for-2026-0b8fbceac342c05cPharmaRadar360en2026-09-24T13:00:03.000ZRemote health advice: weekly bulletins for 2026https://www.pharmaradar360.com/article/national-ambulance-syndromic-surveillance-weekly-bulletins-2026-6dee157afd1fba75PharmaRadar360en2026-09-24T13:00:03.000ZNational ambulance syndromic surveillance: weekly bulletins 2026https://www.pharmaradar360.com/article/gp-out-of-hours-syndromic-surveillance-weekly-bulletins-for-2026-f212a5a75078c06ePharmaRadar360en2026-09-24T13:00:03.000ZGP out-of-hours syndromic surveillance: weekly bulletins for 2026https://www.pharmaradar360.com/article/gp-in-hours-weekly-bulletins-for-2026-dfebf391f225843dPharmaRadar360en2026-09-24T13:00:03.000ZGP in-hours: weekly bulletins for 2026https://www.pharmaradar360.com/article/emergency-department-weekly-bulletins-for-2026-08abcdde2881ef86PharmaRadar360en2026-09-24T13:00:03.000ZEmergency department: weekly bulletins for 2026https://www.pharmaradar360.com/article/why-you-need-new-experts-for-ai-validation-canva-01eb9bca8a13d35cPharmaRadar360en2026-09-24T13:00:00.000ZWhy You Need New Experts for AI Validation Canvahttps://www.pharmaradar360.com/article/acrp-fellow-advocates-for-workforce-support-recognition-of-the-human-element-at-adb76937931c263cPharmaRadar360en2026-09-24T12:59:40.000ZACRP Fellow Advocates for Workforce Support, Recognition of the “Human Element” at the Heart of Clinical Researchhttps://www.pharmaradar360.com/article/supply-chain-signal-how-policy-pressures-are-converging-on-pharma-657d9fba122364cbPharmaRadar360en2026-09-24T12:59:23.000ZSupply Chain Signal: How Policy Pressures Are Converging on Pharmahttps://www.pharmaradar360.com/article/gmp-inspections-timelines-a-critical-regulatory-challenge-for-russian-pharmaceut-e7dc698ef5110745PharmaRadar360en2026-09-24T12:53:11.000ZGMP inspections timelines: a critical regulatory challenge for Russian pharmaceutical manufacturershttps://www.pharmaradar360.com/article/fda-upgrades-vitruvias-thyroid-drug-recall-to-highest-risk-level-628ccd913b0388b6PharmaRadar360en2026-09-24T12:51:01.000ZFDA Upgrades Vitruvias Thyroid Drug Recall to Highest Risk Levelhttps://www.pharmaradar360.com/article/health-equity-strategies-reports-and-tools-c0ffe1b40e5cb25dPharmaRadar360en2026-09-24T12:43:28.000ZHealth equity strategies, reports and toolshttps://www.pharmaradar360.com/article/bionation-2026-makes-the-case-for-canadian-biotech-as-a-national-priority-ad639bc356d65e3dPharmaRadar360en2026-09-24T12:32:08.000ZBIONATION 2026 Makes the Case for Canadian Biotech as a National Priorityhttps://www.pharmaradar360.com/article/bionation-2026-makes-the-case-for-canadian-biotech-as-a-national-priority-associ-a2e87b82d11840ddPharmaRadar360en2026-09-24T12:32:08.000ZBIONATION 2026 Makes the Case for Canadian Biotech as a National Priority | Associated Press | syndication newshttps://www.pharmaradar360.com/article/bionation-2026-makes-the-case-for-canadian-biotech-as-a-national-priority-b9989c6df729a5efPharmaRadar360en2026-09-24T12:32:00.000ZBIONATION 2026 Makes the Case for Canadian Biotech as a National Priorityhttps://www.pharmaradar360.com/article/complete-routine-immunisation-schedule-f183272f6e9e9379PharmaRadar360en2026-09-24T12:27:44.000ZComplete routine immunisation schedulehttps://www.pharmaradar360.com/article/merck-sees-pivotal-victory-for-3b-eye-disease-prospect-c531284e9416942cPharmaRadar360en2026-09-24T12:15:31.000ZMerck sees pivotal victory for $3B eye disease prospecthttps://www.pharmaradar360.com/article/imunon-makes-the-frontline-case-for-phase-3-imnn-001-study-14-7-month-os-signal-868d8772ba1a6b61PharmaRadar360en2026-09-24T12:11:02.000ZIMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Planhttps://www.pharmaradar360.com/article/the-first-patient-has-received-a-germ-fighting-gel-being-tested-for-infected-dia-5fb89581d66b5d03PharmaRadar360en2026-09-24T12:02:00.000ZThe first patient has received a germ-fighting gel being tested for infected diabetic foot ulcers.https://www.pharmaradar360.com/article/likoralltm-patient-lift-systems-d7a7892377661e3ePharmaRadar360en2026-09-24T12:00:00.000ZLikorall™ Patient Lift Systemshttps://www.pharmaradar360.com/article/interstimtm-systems-8f983b571970ef4cPharmaRadar360en2026-09-24T12:00:00.000ZInterStim™ Systemshttps://www.pharmaradar360.com/article/daewoong-pharmaceutical-presents-baseline-characteristics-of-104-patients-in-glo-8ddd06580f20c1fePharmaRadar360en2026-09-24T12:00:00.000ZDaewoong Pharmaceutical Presents Baseline Characteristics of 104 Patients in Global Phase 2 Trial for IPF Drug Candidate 'Bersiporocin' at ERS 2026https://www.pharmaradar360.com/article/why-a-us-senator-wants-a-biotech-leader-in-the-white-house-who-has-the-president-b6e7dabb5e589933PharmaRadar360en2026-09-24T12:00:00.000ZWhy a US senator wants a biotech leader in the White House who ‘has the president’s ear’https://www.pharmaradar360.com/article/atyr-pharma-atyr-gains-5-after-securing-fda-protocol-approval-for-phase-3-sarcoi-16bd40c5d8cb33aePharmaRadar360en2026-09-24T11:50:45.000ZaTyr Pharma (ATYR) Gains 5% After Securing FDA Protocol Approval for Phase 3 Sarcoidosis Studyhttps://www.pharmaradar360.com/article/moderna-begins-phase-1-clinical-trial-of-ebola-vaccine-against-strain-behind-drc-0f15edae8af6e558PharmaRadar360en2026-09-24T11:42:06.000ZModerna begins Phase 1 clinical trial of Ebola vaccine against strain behind DRC outbreakhttps://www.pharmaradar360.com/article/health-protection-report-volume-20-2026-f9e0b8a49f9df3c3PharmaRadar360en2026-09-24T11:30:05.000ZHealth Protection Report volume 20 (2026)https://www.pharmaradar360.com/article/prac-september-2026-veiligheidsonderzoek-naar-injecteerbare-ijzerhoudende-genees-d3df9ebf3c2363cePharmaRadar360en2026-09-24T11:27:15.000ZPRAC september 2026: veiligheidsonderzoek naar injecteerbare ijzerhoudende geneesmiddelenhttps://www.pharmaradar360.com/article/arwr-stock-goldman-sachs-resumes-coverage-with-74-target-as-clinical-catalysts-n-54f6027f066b31dcPharmaRadar360en2026-09-24T11:20:57.000ZARWR Stock: Goldman Sachs Resumes Coverage With $74 Target As Clinical Catalysts Nearhttps://www.pharmaradar360.com/article/dhsc-workforce-management-information-62f452371af74327PharmaRadar360en2026-09-24T11:12:11.000ZDHSC: workforce management informationhttps://www.pharmaradar360.com/article/dhsc-workforce-management-information-august-2026-291cf16d23181a61PharmaRadar360en2026-09-24T11:11:46.000ZDHSC: workforce management information August 2026https://www.pharmaradar360.com/article/a-second-measure-favored-the-higher-dose-the-alzheimer-s-drug-narrowly-missed-it-3c1bb4ef41c89852PharmaRadar360en2026-09-24T11:03:43.000ZA second measure favored the higher dose. The Alzheimer’s drug narrowly missed its main test.https://www.pharmaradar360.com/article/flsc-ipo-news-biotech-spac-frazier-life-sciences-acquisition-ii-files-for-a-75-m-d5eab25a2dd31e90PharmaRadar360en2026-09-24T11:01:00.000ZFLSC IPO News - Biotech SPAC Frazier Life Sciences Acquisition II files for a $75 million IPOhttps://www.pharmaradar360.com/article/ono-pharmaceutical-co-ophlf-soars-13-9-is-further-upside-left-in-the-stock-0950027dcda4a100PharmaRadar360en2026-09-24T11:00:00.000ZOno Pharmaceutical Co. (OPHLF) Soars 13.9%: Is Further Upside Left in the Stock?https://www.pharmaradar360.com/article/acadia-pharmaceuticals-announces-phase-3-enabling-topline-results-from-phase-2-r-c918ae34422e8020PharmaRadar360en2026-09-24T11:00:00.000ZAcadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)https://www.pharmaradar360.com/article/healthy-start-extension-application-guidance-84d59c59b495a9a2PharmaRadar360en2026-09-24T10:58:31.000ZHealthy Start extension: application guidancehttps://www.pharmaradar360.com/article/podcast-how-sandoz-plans-to-harness-its-golden-decade-68b53bc08b1c1d6fPharmaRadar360en2026-09-24T10:55:19.000ZPodcast: How Sandoz plans to harness its "golden decade"https://www.pharmaradar360.com/article/enveda-nabs-311m-to-progress-nature-derived-drug-pipeline-55af799b19cd9116PharmaRadar360en2026-09-24T10:52:37.000ZEnveda nabs $311m to progress nature-derived drug pipelinehttps://www.pharmaradar360.com/article/ctt-pharmaceutical-adds-karen-larson-to-board-e7cff323c616d17fPharmaRadar360en2026-09-24T10:49:11.000ZCTT Pharmaceutical Adds Karen Larson to Boardhttps://www.pharmaradar360.com/article/merck-s-remigromig-a-tri-specific-agonist-of-the-wingless-related-integration-si-564f990f527f019dPharmaRadar360en2026-09-24T10:45:00.000ZMerck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edemahttps://www.pharmaradar360.com/article/lilly-s-fda-approved-weekly-insulin-could-mean-over-300-fewer-shots-a-year-than-a8e09cc6f5e4003aPharmaRadar360en2026-09-24T10:45:00.000ZLilly's FDA-approved weekly insulin could mean over 300 fewer shots a year than daily insulinhttps://www.pharmaradar360.com/article/schorr-family-foundation-scholarships-help-two-pharmacy-students-c82a687b573f5292PharmaRadar360en2026-09-24T10:40:51.000ZSchorr Family Foundation Scholarships help two pharmacy studentshttps://www.pharmaradar360.com/article/gohub-ventures-invests-in-swiss-biotech-startup-prevision-medicine-5b7fe1d6af0950f2PharmaRadar360en2026-09-24T10:36:47.000ZGoHub Ventures invests in Swiss biotech startup Prevision Medicinehttps://www.pharmaradar360.com/article/why-gilead-can-t-stop-talking-about-its-ambitions-in-immunology-4e9a973d5ffa33b5PharmaRadar360en2026-09-24T10:34:09.000ZWhy Gilead can’t stop talking about its ambitions in immunologyhttps://www.pharmaradar360.com/article/working-for-dhsc-7fde6c0568507ce7PharmaRadar360en2026-09-24T10:31:18.000ZWorking for DHSChttps://www.pharmaradar360.com/article/krystal-biotech-stock-initiated-at-buy-by-goldman-sachs-06ed5dbd214c1bc0PharmaRadar360en2026-09-24T10:26:45.000ZKrystal Biotech stock initiated at buy by Goldman Sachshttps://www.pharmaradar360.com/article/what-actually-went-wrong-when-a-phase-3-trial-fails-q-a-with-dr-remo-moomiaie-qa-c88ca5967f76fd20PharmaRadar360en2026-09-24T10:06:38.000ZWhat Actually Went Wrong When a Phase 3 Trial Fails: Q&A with Dr. Remo Moomiaie-Qajarhttps://www.pharmaradar360.com/article/medicinova-announces-completion-of-last-patient-last-visit-in-the-double-blind-p-cfde8abb806f2672PharmaRadar360en2026-09-24T10:06:08.000ZMediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)https://www.pharmaradar360.com/article/china-is-excelling-in-health-tech-that-s-good-news-for-the-world-30d79eb43ed47a25PharmaRadar360en2026-09-24T10:05:26.000ZChina is excelling in health tech. That’s good news for the worldhttps://www.pharmaradar360.com/article/0a2b89983de35c79PharmaRadar360en2026-09-24T10:02:05.000ZΠροσωρινός πίνακας κατάταξης υποψηφίων συνεργατών του ΕΟΦ με καθεστώς ΑΠΥ ειδικότητας ΔΕ Οδηγώνhttps://www.pharmaradar360.com/article/fda-and-atyr-align-on-a-planned-lung-disease-drug-trial-for-up-to-about-372-pati-f7ff287b591c8a1ePharmaRadar360en2026-09-24T10:00:00.000ZFDA and aTyr align on a planned lung disease drug trial for up to about 372 patients.https://www.pharmaradar360.com/article/2026-909-27-2026-c0fc667f86e8537cPharmaRadar360en2026-09-24T09:56:36.000ZΑνακοίνωση σχετικά με τον ΚΑΝΟΝΙΣΜΟ (ΕΕ) 2026/909 ΤΗΣ ΕΠΙΤΡΟΠΗΣ της 27ης Απριλίου 2026https://www.pharmaradar360.com/article/caliway-reports-phase-ii-success-for-dercum-s-disease-therapy-d74330c3d4bd909cPharmaRadar360en2026-09-24T09:49:55.000ZCaliway reports Phase II success for Dercum's disease therapyhttps://www.pharmaradar360.com/article/anti-vax-ally-of-rfk-jr-faces-senate-showdown-in-bid-to-run-fda-c94a6418d0603cf5PharmaRadar360en2026-09-24T09:33:02.000ZAnti-vax ally of RFK Jr. faces Senate showdown in bid to run FDAhttps://www.pharmaradar360.com/article/a-visual-guide-to-vaccines-9bd59f2f55e933f2PharmaRadar360en2026-09-24T09:26:47.000ZA visual guide to vaccineshttps://www.pharmaradar360.com/article/biotech-stocks-at-52-week-highs-tkno-mrna-atrc-ilmn-db25e51232f70ef0PharmaRadar360en2026-09-24T09:26:00.000ZBiotech Stocks At 52-Week Highs - TKNO, MRNA, ATRC, ILMNhttps://www.pharmaradar360.com/article/basecamp-research-secures-140m-for-ai-driven-therapies-1fb496172a1d55e7PharmaRadar360en2026-09-24T09:15:40.000ZBasecamp Research secures $140m for AI-driven therapieshttps://www.pharmaradar360.com/article/saudi-arabia-s-1-3-billion-biotech-push-following-riyadh-summit-1a760444b9610383PharmaRadar360en2026-09-24T09:05:00.000ZSaudi Arabia’s $1.3 billion biotech push following Riyadh summithttps://www.pharmaradar360.com/article/cspc-pharmaceutical-initiates-phase-iii-trial-of-hb1801-for-advanced-breast-canc-722961134acadef9PharmaRadar360en2026-09-24T09:04:41.000ZCSPC Pharmaceutical Initiates Phase III Trial Of HB1801 For Advanced Breast Cancer In Chinahttps://www.pharmaradar360.com/article/abortion-pills-vaccines-and-food-safety-f-d-a-nominee-heidi-overton-faces-senate-8657d6ea819eb9f9PharmaRadar360en2026-09-24T09:02:43.000ZAbortion Pills, Vaccines and Food Safety: F.D.A. Nominee Heidi Overton Faces Senate Confirmation Hearinghttps://www.pharmaradar360.com/article/japan-s-kobayashi-pharmaceutical-considering-going-private-under-japan-uk-invest-b7d7019e91da6c88PharmaRadar360en2026-09-24T09:01:56.000ZJapan's Kobayashi Pharmaceutical Considering Going Private Under Japan-UK Investment Fund Consortium, Bloomberg News Sayshttps://www.pharmaradar360.com/article/environmental-monitoring-following-the-grenfell-tower-fire-85d5cc3f2b36adbcPharmaRadar360en2026-09-24T09:01:04.000ZEnvironmental monitoring following the Grenfell Tower firehttps://www.pharmaradar360.com/article/fda-advisory-panel-endorses-grail-blood-test-for-cancer-saying-benefits-outweigh-839e5eff0a011929PharmaRadar360en2026-09-24T09:00:11.000ZFDA advisory panel endorses Grail blood test for cancer, saying benefits outweigh riskshttps://www.pharmaradar360.com/article/the-phd-to-biotech-series-clarifying-your-direction-before-you-leave-academia-32528df980be6fabPharmaRadar360en2026-09-24T08:58:56.000ZThe PhD to biotech series: Clarifying your direction before you leave academiahttps://www.pharmaradar360.com/article/daewoong-pharmaceutical-presents-baseline-characteristics-of-104-patients-in-glo-9e2412cd0063c035PharmaRadar360en2026-09-24T08:44:00.000ZDaewoong Pharmaceutical Presents Baseline Characteristics of 104 Patients in Global Phase 2 Trial for IPF Drug Candidate 'Bersiporocin' at ERS 2026https://www.pharmaradar360.com/article/pre-release-access-lists-cover-programme-quarterly-data-428cef6b96303d41PharmaRadar360en2026-09-24T08:30:20.000ZPre-release access lists: COVER programme quarterly datahttps://www.pharmaradar360.com/article/pseudomonas-aeruginosa-bacteraemia-annual-data-1d797b39720d627dPharmaRadar360en2026-09-24T08:30:18.000ZPseudomonas aeruginosa bacteraemia: annual datahttps://www.pharmaradar360.com/article/mssa-bacteraemia-annual-data-f528c463d0bdaf78PharmaRadar360en2026-09-24T08:30:17.000ZMSSA bacteraemia: annual datahttps://www.pharmaradar360.com/article/klebsiella-species-bacteraemia-annual-data-503a503e52f5c85bPharmaRadar360en2026-09-24T08:30:17.000ZKlebsiella species bacteraemia: annual datahttps://www.pharmaradar360.com/article/clostridioides-difficile-c-difficile-infection-cdi-annual-data-8aca3e044b7619f2PharmaRadar360en2026-09-24T08:30:17.000ZClostridioides difficile (C difficile) infection (CDI): annual datahttps://www.pharmaradar360.com/article/escherichia-coli-bacteraemia-annual-data-3f475f96b5a9b5cbPharmaRadar360en2026-09-24T08:30:16.000ZEscherichia coli bacteraemia: annual datahttps://www.pharmaradar360.com/article/survey-of-adult-carers-in-england-d418d708ba824a58PharmaRadar360en2026-09-24T08:30:16.000ZSurvey of adult carers in Englandhttps://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-surveillance-reports-2026-to-2027-season-1cc078fa257f8153PharmaRadar360en2026-09-24T08:30:11.000ZNational norovirus and rotavirus surveillance reports: 2026 to 2027 seasonhttps://www.pharmaradar360.com/article/group-a-streptococcal-infections-seasonal-activity-in-england-2025-to-2026-ce123cc7682acde2PharmaRadar360en2026-09-24T08:30:11.000ZGroup A streptococcal infections: seasonal activity in England, 2025 to 2026https://www.pharmaradar360.com/article/salmonella-statistical-releases-5659a2d745797007PharmaRadar360en2026-09-24T08:30:10.000ZSalmonella statistical releaseshttps://www.pharmaradar360.com/article/gastrointestinal-infections-and-outbreak-statistics-for-england-05961f6c3dda1ec2PharmaRadar360en2026-09-24T08:30:10.000ZGastrointestinal infections and outbreak statistics for Englandhttps://www.pharmaradar360.com/article/childhood-vaccine-coverage-provisional-monthly-data-england-2026-29f210faf64d1d4dPharmaRadar360en2026-09-24T08:30:10.000ZChildhood vaccine coverage: provisional monthly data (England) 2026https://www.pharmaradar360.com/article/staphylococcus-aureus-guidance-data-and-analysis-a8912dd7bdb60a2dPharmaRadar360en2026-09-24T08:30:10.000ZStaphylococcus aureus: guidance, data and analysishttps://www.pharmaradar360.com/article/pertussis-guidance-data-and-analysis-03c0c3d9c5f593d2PharmaRadar360en2026-09-24T08:30:10.000ZPertussis: guidance, data and analysishttps://www.pharmaradar360.com/article/rubella-confirmed-cases-and-notifications-926536a7ab5f7350PharmaRadar360en2026-09-24T08:30:09.000ZRubella: confirmed cases and notificationshttps://www.pharmaradar360.com/article/pertussis-laboratory-confirmed-cases-reported-in-england-2026-db4e82e10f96250aPharmaRadar360en2026-09-24T08:30:09.000ZPertussis: laboratory confirmed cases reported in England 2026https://www.pharmaradar360.com/article/gram-negative-mrsa-and-mssa-bacteraemia-and-c-difficile-infections-annual-epidem-f5bcd757f0f31131PharmaRadar360en2026-09-24T08:30:09.000ZGram-negative, MRSA and MSSA bacteraemia and C. difficile infections: annual epidemiological commentarieshttps://www.pharmaradar360.com/article/cover-of-vaccination-evaluated-rapidly-cover-programme-2026-to-2027-quarterly-da-c123be05410e88f7PharmaRadar360en2026-09-24T08:30:08.000ZCover of vaccination evaluated rapidly (COVER) programme 2026 to 2027: quarterly datahttps://www.pharmaradar360.com/article/cover-of-vaccination-evaluated-rapidly-cover-programme-2025-to-2026-quarterly-da-ec5c68eb5b9089f9PharmaRadar360en2026-09-24T08:30:08.000ZCover of vaccination evaluated rapidly (COVER) programme 2025 to 2026: quarterly datahttps://www.pharmaradar360.com/article/mumps-confirmed-cases-and-notifications-c7fa17868bb576d7PharmaRadar360en2026-09-24T08:30:08.000ZMumps: confirmed cases and notificationshttps://www.pharmaradar360.com/article/cover-of-vaccination-evaluated-rapidly-cover-programme-statistics-ba0b6fc132b9bc62PharmaRadar360en2026-09-24T08:30:08.000ZCover of vaccination evaluated rapidly (COVER) programme statisticshttps://www.pharmaradar360.com/article/healthcare-associated-infections-hcai-statistics-b7d400e2cae94ffcPharmaRadar360en2026-09-24T08:30:07.000ZHealthcare-associated infections (HCAI) statisticshttps://www.pharmaradar360.com/article/ukhsa-priorities-in-2026-to-2027-1952003048c98805PharmaRadar360en2026-09-24T08:30:06.000ZUKHSA priorities in 2026 to 2027https://www.pharmaradar360.com/article/ukhsa-annual-remit-letters-951394235efaad03PharmaRadar360en2026-09-24T08:30:06.000ZUKHSA annual remit lettershttps://www.pharmaradar360.com/article/healthcare-associated-infections-hcai-qmi-report-3d3a05bef1af6387PharmaRadar360en2026-09-24T08:30:05.000ZHealthcare-associated infections (HCAI) QMI reporthttps://www.pharmaradar360.com/article/survey-of-adult-carers-in-england-2025-to-2026-report-dd94c8c57d1015b9PharmaRadar360en2026-09-24T08:30:04.000ZSurvey of adult carers in England: 2025 to 2026 reporthttps://www.pharmaradar360.com/article/gram-negative-mrsa-and-mssa-bacteraemia-and-c-difficile-infections-annual-epidem-0349e3e77f352fa2PharmaRadar360en2026-09-24T08:30:04.000ZGram-negative, MRSA and MSSA bacteraemia and C. difficile infections: annual epidemiological reports 2022 to 2025https://www.pharmaradar360.com/article/mrsa-bacteraemia-annual-data-41045b47b36919adPharmaRadar360en2026-09-24T08:30:04.000ZMRSA bacteraemia: annual datahttps://www.pharmaradar360.com/article/gram-negative-mrsa-and-mssa-bacteraemia-and-c-difficile-infections-annual-epidem-15eaf59b1e073a25PharmaRadar360en2026-09-24T08:30:00.000ZGram-negative, MRSA and MSSA bacteraemia and C. difficile infections: annual epidemiological commentary 2025 to 2026https://www.pharmaradar360.com/article/zawya-jordan-innovation-to-boost-pharmaceutical-industry-expansion-competitivene-176d20ac670397c0PharmaRadar360en2026-09-24T08:06:40.000ZZAWYA: Jordan: Innovation to boost pharmaceutical industry expansion, competitivenesshttps://www.pharmaradar360.com/article/bristol-myers-squibb-announces-265-additional-job-cuts-9a849e8b43466d86PharmaRadar360en2026-09-24T07:56:21.000ZBristol Myers Squibb announces 265 additional job cutshttps://www.pharmaradar360.com/article/five-reputable-food-safety-pharmaceutical-analysis-testing-comp-8d1fad0593c07239PharmaRadar360en2026-09-24T07:46:09.000ZFive Reputable Food Safety & Pharmaceutical Analysis Testing Comphttps://www.pharmaradar360.com/article/sweden-sees-rise-in-reported-adverse-reactions-to-semaglutide-c726e3240e922ecdPharmaRadar360en2026-09-24T07:32:43.000ZSweden sees rise in reported adverse reactions to semaglutidehttps://www.pharmaradar360.com/article/medienmitteilung-klinische-forschung-unter-druck-die-schweiz-verliert-den-anschl-f10a4dd63d4b7ad6PharmaRadar360en2026-09-24T07:12:57.000ZMedienmitteilung: Klinische Forschung unter Druck: Die Schweiz verliert den Anschlusshttps://www.pharmaradar360.com/article/astellas-starts-phase-3-trial-of-setidegrasib-vs-docetaxel-in-kras-g12d-lung-can-04158db7875be88dPharmaRadar360en2026-09-24T06:43:26.000ZAstellas Starts Phase 3 Trial of Setidegrasib vs Docetaxel in KRAS G12D Lung Cancerhttps://www.pharmaradar360.com/article/aurion-biotech-completes-enrolment-in-pivotal-phase-3-astra-trial-of-aurn001-054fc721ae97f0f7PharmaRadar360en2026-09-24T06:41:03.000ZAurion Biotech completes enrolment in pivotal Phase 3 ASTRA trial of AURN001https://www.pharmaradar360.com/article/2026-1816dbb998f2b4ffPharmaRadar360en2026-09-24T06:39:42.000ZΓενόσημα Αυγούστου 2026 _ Προτεινόμενες Τιμές προς Διαβούλευσηhttps://www.pharmaradar360.com/article/lilly-puts-up-100m-plus-billions-on-the-backend-to-form-5-target-deal-with-china-6c61ef54a1649f1cPharmaRadar360en2026-09-24T06:39:26.000ZLilly puts up $100M, plus billions on the backend, to form 5-target deal with China's InnoCarehttps://www.pharmaradar360.com/article/8ebee4139de8b40aPharmaRadar360en2026-09-24T06:36:45.000ZΔήλωση Αποθεμάτων Φαρμάκων Ανθρώπινης Χρήσηςhttps://www.pharmaradar360.com/article/europe-s-opportunity-to-capture-the-value-in-china-biotech-mcdermott-will-schult-085f959c32a8b182PharmaRadar360en2026-09-24T06:36:00.000ZEurope’s opportunity to capture the value in China biotech. McDermott Will & Schulte's Emmanuelle Trombe and Anthony Paronneau talk to Investors in Healthcarehttps://www.pharmaradar360.com/article/iii-imagination-a496c4076e536916PharmaRadar360en2026-09-24T06:30:00.000Zロシュ社によるセーファキセルセンナトリウムに関する発表について（第III相IMAGINATION試験の中間解析結果）https://www.pharmaradar360.com/article/roche-s-announcement-regarding-sefaxersen-announcement-of-interim-analysis-resul-2b62b1533500f4e4PharmaRadar360en2026-09-24T06:30:00.000ZRoche’s Announcement Regarding Sefaxersen (Announcement of Interim Analysis Results from the Phase III IMAGINATION Study)https://www.pharmaradar360.com/article/senators-to-question-fda-nominee-about-her-views-on-abortion-pill-and-vaccines-7927482d11e62167PharmaRadar360en2026-09-24T06:10:03.000ZSenators to question FDA nominee about her views on abortion pill and vaccineshttps://www.pharmaradar360.com/article/us-mrna-player-arcturus-buys-belgian-biotech-myneo-d16ed4fa7c90683bPharmaRadar360en2026-09-24T05:46:56.000ZUS mRNA player Arcturus buys Belgian biotech MyNeohttps://www.pharmaradar360.com/article/from-scientific-excellence-to-industrial-implementation-7d269cad5f6bcd35PharmaRadar360en2026-09-24T05:31:01.000ZFrom Scientific Excellence to Industrial Implementationhttps://www.pharmaradar360.com/article/scancell-completes-up-to-us-25-million-in-debt-financing-providing-optionality-a-bf9b9582e6d48052PharmaRadar360en2026-09-24T05:02:51.000ZScancell completes up to US$25 million in debt financing, providing optionality alongside equity investment to finance iSCIB1+ phase 3 developmenthttps://www.pharmaradar360.com/article/beyond-open-innovation-how-to-make-pharma-biotech-collab-work-at-scale-56c6678157e4dce8PharmaRadar360en2026-09-24T05:00:01.000ZBeyond Open Innovation: How to Make Pharma–Biotech Collab Work at Scalehttps://www.pharmaradar360.com/article/small-biotech-can-outsource-the-work-but-not-the-thinking-62440c8a0f80ffa8PharmaRadar360en2026-09-24T04:48:20.000ZSmall Biotech Can Outsource The Work, But Not The Thinkinghttps://www.pharmaradar360.com/article/sls-ibrx-eye-green-month-as-biotech-etf-gains-steam-analyst-sees-continued-oppor-6a1aa66cf3396998PharmaRadar360en2026-09-24T04:30:37.000ZSLS, IBRX Eye Green Month As Biotech ETF Gains Steam: Analyst Sees ‘Continued Opportunities’ In Immuno-Oncologyhttps://www.pharmaradar360.com/article/oncolytics-biotech-nasdaq-oncy-trading-down-5-2-time-to-sell-0ef78dc82ada9778PharmaRadar360en2026-09-24T04:23:03.000ZOncolytics Biotech (NASDAQ:ONCY) Trading Down 5.2% - Time to Sell?https://www.pharmaradar360.com/article/fda-suspends-licence-of-big-basket-outlet-2-others-in-pune-983a0d3619458216PharmaRadar360en2026-09-24T04:01:00.000ZFDA suspends licence of Big Basket outlet, 2 others in Punehttps://www.pharmaradar360.com/article/forge-nano-and-nanexa-enter-joint-development-agreement-to-advance-manufacturing-ba5c9042fb0dd3d3PharmaRadar360en2026-09-24T03:43:00.000ZForge Nano and Nanexa Enter Joint Development Agreement to Advance Manufacturing for ALD-Coated PharmaShell® Long-Acting Injectable Medicineshttps://www.pharmaradar360.com/article/relay-therapeutics-stock-in-focus-as-phase-3-trial-begins-ae162c061bbbe4dePharmaRadar360en2026-09-24T03:40:53.000ZRelay Therapeutics Stock In Focus As Phase 3 Trial Beginshttps://www.pharmaradar360.com/article/beyond-gravity-what-happens-when-biotech-leaves-earth-f07a29aa63bed1c2PharmaRadar360en2026-09-24T03:19:36.000ZBeyond gravity — What happens when biotech leaves Earth?https://www.pharmaradar360.com/article/pharmaceutical-fine-chemicals-market-research-by-the-business-research-company-h-d995cc154853c988PharmaRadar360en2026-09-24T02:15:00.000ZPharmaceutical Fine Chemicals Market Research By The Business Research Company, Highlights Future Industry Forecastshttps://www.pharmaradar360.com/article/denmark-s-novo-nordisk-drives-pharmaceutical-growth-amid-economi-614c7030a4d75324PharmaRadar360en2026-09-24T01:30:52.000ZDenmark's Novo Nordisk Drives Pharmaceutical Growth Amid Economihttps://www.pharmaradar360.com/article/veraxa-biotech-nasdaq-vrxa-appoints-raju-willener-as-chief-financial-officer-f28b533ec19df462PharmaRadar360en2026-09-24T01:29:31.000ZVERAXA Biotech (NASDAQ: VRXA) Appoints Raju Willener as Chief Financial Officerhttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-limited-teva-stock-price-news-quote-and-history-fc990b185865c912PharmaRadar360en2026-09-24T01:13:46.000ZTeva Pharmaceutical Industries Limited (TEVA) stock price, news, quote and historyhttps://www.pharmaradar360.com/article/otsuka-presents-new-phase-3b-results-for-simtriyo-centanafadine-highlighting-con-1a29f0f899bb75bdPharmaRadar360en2026-09-24T01:00:00.000ZOtsuka Presents New Phase 3b Results for SIMTRIYO® (centanafadine) Highlighting Consistent Improvements Across ADHD Symptoms, Anxiety, and Associated Features in Adults with ADHD and Comorbid Anxiety Disorders at Psych Congress 2026https://www.pharmaradar360.com/article/south-korea-s-cellid-sells-control-to-huniverse-global-bluemtec-goes-to-kolmar-g-3f9c640f1bbe8a4bPharmaRadar360en2026-09-24T00:55:00.000ZSouth Korea's Cellid Sells Control to Huniverse Global; BlueMTec Goes to Kolmar Grouphttps://www.pharmaradar360.com/article/state-street-spdr-s-p-biotech-etf-xbi-stock-price-news-quote-and-history-c439df664c2384a2PharmaRadar360en2026-09-24T00:48:53.000ZState Street SPDR S&P Biotech ETF (XBI) stock price, news, quote and historyhttps://www.pharmaradar360.com/article/hlb-wins-fda-nod-for-fgfr2-cholangiocarcinoma-drug-targets-q4-us-launch-chosunbi-1f8b2d48bd4073d8PharmaRadar360en2026-09-24T00:36:00.000ZHLB wins FDA nod for FGFR2 cholangiocarcinoma drug, targets Q4 US launch - CHOSUNBIZhttps://www.pharmaradar360.com/article/kringle-pharma-seeks-u-s-phase-3-trial-for-spinal-cord-injury-drug-14edbc70749803b0PharmaRadar360en2026-09-24T00:33:11.000ZKringle Pharma Seeks U.S. Phase 3 Trial for Spinal Cord Injury Drughttps://www.pharmaradar360.com/article/gsk-filed-form-6-k-ad72045ab683f604PharmaRadar360en2026-09-24T00:00:00.000ZGSK filed Form 6-Khttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-d3f013665ddaf50fPharmaRadar360en2026-09-24T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-443ea740c7e69f2ePharmaRadar360en2026-09-24T00:00:00.000Znatco records %e2%82%b9794 4 crore consolidated revenue and %e2%82%b9206 5 crore of profit after tax for q1 fy27https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-38a38cc651371f60PharmaRadar360en2026-09-24T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-f5553c80e908f2c8PharmaRadar360en2026-09-24T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-06139b71cc0c153bPharmaRadar360en2026-09-24T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-233ae5c1e061737fPharmaRadar360en2026-09-24T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-172118f52588403ePharmaRadar360en2026-09-24T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-713ee91cfbca7345PharmaRadar360en2026-09-24T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-6444b7eb9bd533c5PharmaRadar360en2026-09-24T00:00:00.000Znatco pharma limited announces conclusion of us fda inspection at visakhapatnam andhra pradesh finished dosage formulations fdf unithttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-b13e77112b2bd209PharmaRadar360en2026-09-24T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-9a2ffc4b39550df0PharmaRadar360en2026-09-24T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-5d34321111493c16PharmaRadar360en2026-09-24T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-9a0cdccf6bfe7223PharmaRadar360en2026-09-24T00:00:00.000Zinvestment of us 14 million in egenesis inc by natco pharma canada inc and natco pharma south africa proprietary limitedhttps://www.pharmaradar360.com/article/home-page-17a9ae42e7bab440PharmaRadar360en2026-09-24T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/health-center-program-performance-period-extensions-0f0cd04cdb1c8a07PharmaRadar360en2026-09-24T00:00:00.000ZHealth Center Program Performance Period Extensionshttps://www.pharmaradar360.com/article/national-institute-on-deafness-and-other-communication-disorders-notice-of-close-ba042779be6415ecPharmaRadar360en2026-09-24T00:00:00.000ZNational Institute on Deafness and Other Communication Disorders; Notice of Closed Meetinghttps://www.pharmaradar360.com/article/announcement-of-the-intent-to-award-a-single-source-cooperative-agreement-to-int-196740f909292d40PharmaRadar360en2026-09-24T00:00:00.000ZAnnouncement of the Intent To Award a Single-Source Cooperative Agreement to International Rescue Committee in New York, New Yorkhttps://www.pharmaradar360.com/article/improving-patient-access-to-deceased-donor-islet-cells-and-cell-products-request-7c8bf0c1fd2bd478PharmaRadar360en2026-09-24T00:00:00.000ZImproving Patient Access to Deceased Donor Islet Cells and Cell Products; Request for Informationhttps://www.pharmaradar360.com/article/bulk-manufacturer-of-controlled-substances-application-cayman-chemical-company-83551c67b2dddf3ePharmaRadar360en2026-09-24T00:00:00.000ZBulk Manufacturer of Controlled Substances Application: Cayman Chemical Companyhttps://www.pharmaradar360.com/article/bulk-manufacturer-of-controlled-substances-application-eli-elsohly-laboratories-7b874ac6769188b4PharmaRadar360en2026-09-24T00:00:00.000ZBulk Manufacturer of Controlled Substances Application: Eli-Elsohly Laboratorieshttps://www.pharmaradar360.com/article/importer-of-controlled-substances-application-fisher-clinical-services-inc-i-22f4ec8f816e8d51PharmaRadar360en2026-09-24T00:00:00.000ZImporter of Controlled Substances Application: Fisher Clinical Services, Inc. (I)https://www.pharmaradar360.com/article/importer-of-controlled-substances-application-cambridge-isotope-laboratories-inc-339a6737685ac403PharmaRadar360en2026-09-24T00:00:00.000ZImporter of Controlled Substances Application: Cambridge Isotope Laboratories, Inc.https://www.pharmaradar360.com/article/bulk-manufacturer-of-controlled-substances-application-cambridge-isotope-laborat-5e9cedccc508e97dPharmaRadar360en2026-09-24T00:00:00.000ZBulk Manufacturer of Controlled Substances Application: Cambridge Isotope Laboratories, Inc.https://www.pharmaradar360.com/article/request-for-information-medicare-part-d-reasonable-and-relevant-pharmacy-contrac-a32ed7dcd8d4274ePharmaRadar360en2026-09-24T00:00:00.000ZRequest for Information; Medicare Part D Reasonable and Relevant Pharmacy Contracting Standardshttps://www.pharmaradar360.com/article/comparative-evaluation-of-levels-of-vitamin-d-and-cementum-thickness-and-clinica-56654c30b5b58af4PharmaRadar360en2026-09-24T00:00:00.000ZComparative Evaluation of Levels of Vitamin D and Cementum Thickness and Clinical Attachment Level in Periodontitis with and without Type 2 Diabetes Mellitushttps://www.pharmaradar360.com/article/health-risks-associated-with-traumatic-exposures-among-flood-disaster-victims-in-5b55d48739ec2191PharmaRadar360en2026-09-24T00:00:00.000ZHealth Risks Associated with Traumatic Exposures Among Flood Disaster Victims in South-South Nigeria.https://www.pharmaradar360.com/article/precision-medicine-in-diffuse-large-b-cell-lymphoma-integrating-molecular-biomar-e12408836930ea28PharmaRadar360en2026-09-24T00:00:00.000ZPrecision medicine in diffuse large B-cell lymphoma: Integrating molecular biomarkers, targeted therapies, and prognostic toolshttps://www.pharmaradar360.com/article/efficacy-of-transcatheter-arterial-embolization-plus-targeted-chemotherapy-for-a-dfcd1446063adaccPharmaRadar360en2026-09-24T00:00:00.000ZEfficacy of transcatheter arterial embolization plus targeted chemotherapy for advanced hepatocellular carcinoma: A case report and literature reviewhttps://www.pharmaradar360.com/article/tubulocystic-renal-cell-carcinoma-with-aggressive-behavior-insights-from-molecul-d6bf7b15a82a28e4PharmaRadar360en2026-09-24T00:00:00.000ZTubulocystic renal cell carcinoma with aggressive behavior-insights from molecular profiling and single-cell analysis: A case reporthttps://www.pharmaradar360.com/article/correlations-of-the-expression-of-akap95-cx43-cpsf5-6-scffbxl2-and-scffbxo31-in-457d4f522a00c9edPharmaRadar360en2026-09-24T00:00:00.000ZCorrelations of the expression of AKAP95, Cx43, CPSF5/6, SCFFBXL2 and SCFFBXO31 in lung cancer tissueshttps://www.pharmaradar360.com/article/peer-review-report-for-effects-of-transcutaneous-electrical-stimulation-on-perip-083d3f36c265066ePharmaRadar360en2026-09-24T00:00:00.000ZPeer Review Report For: Effects of transcutaneous electrical stimulation on peripheral nerve regeneration after digital neurorrhaphy: A randomized clinical trial. [version 4; peer review: 1 approved, 2 approved with reservations]https://www.pharmaradar360.com/article/snake-antivenom-therapy-for-improving-outcome-in-russell-s-viper-envenomation-sa-8b0d24c073b55439PharmaRadar360en2026-09-24T00:00:00.000ZSnake Antivenom Therapy for Improving Outcome in Russell\'s Viper Envenomation [SAVIOR] – Comparing the Efficacy and Safety of 36 Hours Regimen vs 72 Hours Regimen: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/measuring-nca-outcomes-665cec7eddea2887PharmaRadar360en2026-09-24T00:00:00.000ZMeasuring NCA Outcomeshttps://www.pharmaradar360.com/article/topical-and-systemic-nca-interventions-b325eeec46041d2fPharmaRadar360en2026-09-24T00:00:00.000ZTopical and Systemic NCA Interventionshttps://www.pharmaradar360.com/article/disrupting-hierarchies-of-knowledge-and-strengthening-collective-wisdom-e4b32b559b1fa8d2PharmaRadar360en2026-09-24T00:00:00.000ZDisrupting Hierarchies of Knowledge and Strengthening Collective Wisdomhttps://www.pharmaradar360.com/article/physical-activity-and-exercise-in-pediatric-oncology-conceptual-distinctions-and-0aa355a994cf5c81PharmaRadar360en2026-09-24T00:00:00.000ZPhysical activity and exercise in pediatric oncology: conceptual distinctions and clinical implicationshttps://www.pharmaradar360.com/article/effectiveness-of-vestibular-electrical-stimulation-combined-with-vestibular-reha-eaef322f5700f043PharmaRadar360en2026-09-24T00:00:00.000ZEffectiveness of vestibular electrical stimulation combined with vestibular rehabilitation in chronic unilateral vestibular hypofunction: A randomized controlled trialhttps://www.pharmaradar360.com/article/clinical-and-radiological-outcomes-of-percutaneous-k-wire-fixation-versus-open-r-083f8f81779d12e2PharmaRadar360en2026-09-24T00:00:00.000ZClinical and Radiological Outcomes of Percutaneous K-wire Fixation versus Open Reduction and Internal Fixation for Lisfranc Injuries: A Retrospective Comparative Studyhttps://www.pharmaradar360.com/article/clinical-utility-of-neck-imaging-reporting-and-data-system-in-post-treatment-sur-4b6e85ce06f08615PharmaRadar360en2026-09-24T00:00:00.000ZClinical utility of Neck Imaging Reporting and Data System in post-treatment surveillance of head and neck cancer: A case serieshttps://www.pharmaradar360.com/article/41-metabolic-dysregulation-and-immune-activation-in-vitiligo-unveiling-the-mitoc-a1301e9a89728dbfPharmaRadar360en2026-09-24T00:00:00.000Z41 | METABOLIC DYSREGULATION AND IMMUNE ACTIVATION IN VITILIGO: UNVEILING THE MITOCHONDRIAL AND INFLAMMATORY IMPRINT OF DISEASE PATHOGENESIShttps://www.pharmaradar360.com/article/clinical-characteristics-associated-factors-and-mortality-related-factors-of-pne-f48946eb2b5492ddPharmaRadar360en2026-09-24T00:00:00.000ZClinical Characteristics, Associated Factors, and Mortality-Related Factors of Pneumocystis jirovecii Pneumonia in Patients With Systemic Autoimmune Rheumatic Diseases: A Systematic Review and Meta-analysishttps://www.pharmaradar360.com/article/epidemiology-genetics-clinical-characteristics-and-dietary-risk-factors-of-famil-51e317c6f6c3535bPharmaRadar360en2026-09-24T00:00:00.000ZEpidemiology, genetics, clinical characteristics, and dietary risk factors of familial celiac disease in China: A cross-sectional studyhttps://www.pharmaradar360.com/article/areszt-elektroniczny-a-ograniczenie-skali-stosowania-tymczasowego-aresztowania-e7128e91325fe374PharmaRadar360en2026-09-24T00:00:00.000ZAreszt elektroniczny a ograniczenie skali stosowania tymczasowego aresztowaniahttps://www.pharmaradar360.com/article/critical-care-ultrasound-guided-targeted-volume-management-as-precision-medicine-e319763ba39afdc9PharmaRadar360en2026-09-24T00:00:00.000ZCritical Care Ultrasound-Guided Targeted Volume Management as Precision Medicine: Predicting Clinical and Financial Impactshttps://www.pharmaradar360.com/article/antibiotic-prophylaxis-of-infective-endocarditis-in-dentistry-an-update-on-the-e-9e0a810bc5198dd3PharmaRadar360en2026-09-24T00:00:00.000ZAntibiotic Prophylaxis of Infective Endocarditis in Dentistry: An Update on the ESC, AHA, and NICE Guidelineshttps://www.pharmaradar360.com/article/perioperative-outcomes-of-multivessel-minimally-invasive-coronary-revascularizat-9a13b25dc7aea994PharmaRadar360en2026-09-24T00:00:00.000ZPerioperative Outcomes of Multivessel Minimally Invasive Coronary Revascularization at a Specialized Center: A Retrospective Cohort of Complete Surgical and Planned Hybrid Strategieshttps://www.pharmaradar360.com/article/managing-choledocholithiasis-in-rare-congenital-hepatobiliary-anomalies-a-report-acb1ff9b5c98f97cPharmaRadar360en2026-09-24T00:00:00.000ZManaging Choledocholithiasis in Rare Congenital Hepatobiliary Anomalies: A Report of Three Caseshttps://www.pharmaradar360.com/article/handgrip-strength-relative-to-estimated-skeletal-muscle-mass-and-threshold-defin-7cbe553532899c08PharmaRadar360en2026-09-24T00:00:00.000ZHandgrip Strength Relative to Estimated Skeletal Muscle Mass and Threshold-Defined Physical Performance in Biochemically Controlled Acromegaly: A Cross-Sectional Studyhttps://www.pharmaradar360.com/article/the-impact-of-changes-to-the-payment-restrictions-of-the-national-reimbursement-2a6860a059aca4d9PharmaRadar360en2026-09-24T00:00:00.000ZThe Impact of Changes to the Payment Restrictions of the National Reimbursement Drug List in China: An Empirical Study Employing a Stacked Difference-in-Differences Approachhttps://www.pharmaradar360.com/article/distinct-molecular-landscape-and-clinical-subtype-of-hpv-positive-esophageal-squ-f21f3f790fac31ebPharmaRadar360en2026-09-24T00:00:00.000ZDistinct Molecular Landscape and Clinical Subtype of HPV-Positive Esophageal Squamous Cell Carcinomahttps://www.pharmaradar360.com/article/psoriasis-and-bullous-pemphigoid-an-updated-review-of-clinical-association-targe-419f7c5d8d17be8aPharmaRadar360en2026-09-24T00:00:00.000ZPsoriasis and Bullous Pemphigoid: An Updated Review of Clinical Association, Targeted Therapy Exposures and Therapeutic Implicationshttps://www.pharmaradar360.com/article/role-of-the-gut-microbiome-in-natural-and-synthetic-drug-efficacy-and-safety-a-n-a0533936020f92e9PharmaRadar360en2026-09-24T00:00:00.000ZRole of the Gut Microbiome in Natural and Synthetic Drug Efficacy and Safety: A Narrative Reviewhttps://www.pharmaradar360.com/article/integrated-electrophysiological-and-payload-release-assessment-of-neuronal-respo-f1dfbb664f726b56PharmaRadar360en2026-09-24T00:00:00.000ZIntegrated electrophysiological and payload-release assessment of neuronal responses to antibody-drug conjugates in human iPSC-derived sensory neurons: implications for in vitro neurotoxicity evaluationhttps://www.pharmaradar360.com/article/pediatric-hearing-loss-in-the-universal-newborn-hearing-screening-era-etiologies-f07e99478d594e3dPharmaRadar360en2026-09-24T00:00:00.000ZPediatric hearing loss in the universal newborn hearing screening era: etiologies, risk indicators, and clinical phenotypeshttps://www.pharmaradar360.com/article/incidence-burden-and-associated-factors-of-severe-potential-drug-drug-interactio-000263b0d1b1ca97PharmaRadar360en2026-09-24T00:00:00.000ZIncidence, burden, and associated factors of severe potential drug–drug interactions in intensive care unit patients: a real-world retrospective studyhttps://www.pharmaradar360.com/article/clinical-efficacy-and-safety-evaluation-of-dexmedetomidine-hydrochloride-nasal-s-cffd6c1dca84e355PharmaRadar360en2026-09-24T00:00:00.000ZClinical efficacy and safety evaluation of dexmedetomidine hydrochloride nasal spray for sedation before examinations in children aged 2 to 6 years: protocol for a randomized controlled trialhttps://www.pharmaradar360.com/article/strengthening-the-interpretation-of-longitudinal-eqa-data-through-the-sporadic-i-b9fb7e0dd74e7ef1PharmaRadar360en2026-09-24T00:00:00.000ZStrengthening the interpretation of longitudinal EQA data through the sporadic inclusion of native human sera in general clinical chemistryhttps://www.pharmaradar360.com/article/clinical-efficacy-and-pregnancy-outcomes-of-doxycycline-plus-medroxyprogesterone-67f55084828f7378PharmaRadar360en2026-09-24T00:00:00.000ZClinical efficacy and pregnancy outcomes of doxycycline plus medroxyprogesterone acetate therapy for chronic endometritis in women with recurrent reproductive failure: a prospective cohort studyhttps://www.pharmaradar360.com/article/diagnostic-performance-of-digital-and-clinical-approaches-for-detection-of-podoc-e46d474d49be2259PharmaRadar360en2026-09-24T00:00:00.000ZDiagnostic performance of digital and clinical approaches for detection of podoconiosis by community health workers in Rwanda: a comparison with dermatologist diagnosishttps://www.pharmaradar360.com/article/periodic-fever-aphthous-stomatitis-pharyngitis-adenitis-clinical-manifestations-300bd22349cb7d3aPharmaRadar360en2026-09-24T00:00:00.000ZPeriodic fever, aphthous stomatitis, pharyngitis, adenitis: clinical manifestations, response to steroids, and a practice of online diagnosis and follow-uphttps://www.pharmaradar360.com/article/clinical-contribution-of-mngs-in-the-diagnosis-and-management-of-imported-falcip-f7d332a21c9659e8PharmaRadar360en2026-09-24T00:00:00.000ZClinical contribution of mNGS in the diagnosis and management of imported falciparum malaria in a malaria-free region: a five-case series from northern Chinahttps://www.pharmaradar360.com/article/clinical-trials-on-3d-bioprinted-scaffolds-for-lower-extremity-vascular-diabetic-c3b698dce392e375PharmaRadar360en2026-09-24T00:00:00.000ZClinical trials on 3D bioprinted scaffolds for lower extremity vascular, diabetic and pressure ulcers: a systematic reviewhttps://www.pharmaradar360.com/article/surface-marker-defined-functional-subpopulations-of-mesenchymal-stromal-cells-me-7c9f34b112f5444fPharmaRadar360en2026-09-24T00:00:00.000ZSurface marker-defined functional subpopulations of mesenchymal stromal cells: mechanisms, applications, and clinical translationhttps://www.pharmaradar360.com/article/nonresponse-to-intravitreal-anti-vegf-therapy-for-retinopathy-of-prematurity-cli-2ab291d4acdae5d7PharmaRadar360en2026-09-24T00:00:00.000ZNonresponse to Intravitreal Anti-VEGF Therapy for Retinopathy of Prematurity: Clinical Characteristics and Outcomes After Retreatmenthttps://www.pharmaradar360.com/article/investigation-of-potential-drug-drug-interactions-due-to-linezolid-use-in-anesth-9387ce60364a4bc5PharmaRadar360en2026-09-24T00:00:00.000ZInvestigation of Potential Drug-Drug Interactions Due to Linezolid Use in Anesthesia Intensive Care Unit: A Retrospective Studyhttps://www.pharmaradar360.com/article/therapeutic-effects-of-lentinan-in-gastrointestinal-inflammation-and-carcinogene-6b0c8444a3b58127PharmaRadar360en2026-09-24T00:00:00.000ZTherapeutic effects of Lentinan in gastrointestinal inflammation and carcinogenesis – A scoping review of evidence from preclinical and clinical studieshttps://www.pharmaradar360.com/article/impact-of-an-oral-amino-acid-containing-formulation-on-clinical-and-functional-o-1593243086615193PharmaRadar360en2026-09-24T00:00:00.000ZImpact of an oral amino acid–containing formulation on clinical and functional outcomes in patients with and without heart failure undergoing cardiac rehabilitation program: a pilot studyhttps://www.pharmaradar360.com/article/dna-methylation-biomarkers-from-precancerous-lesions-to-adenocarcinoma-in-the-st-a86ae7786dc25552PharmaRadar360en2026-09-24T00:00:00.000ZDNA Methylation Biomarkers: From Precancerous Lesions to Adenocarcinoma in the Stomach and Esophagushttps://www.pharmaradar360.com/article/vespula-spp-venom-immunotherapy-basophil-excitability-and-fc-ri-fc-riib-expressi-9fb9de0999d796fePharmaRadar360en2026-09-24T00:00:00.000ZVespula spp. venom immunotherapy: basophil excitability and FcεRI/FcγRIIb expressionhttps://www.pharmaradar360.com/article/effect-of-pea-protein-enriched-snacks-and-vitamin-d-supplementation-on-the-progr-90b2d33384ecf18cPharmaRadar360en2026-09-24T00:00:00.000ZEffect of pea protein-enriched snacks and vitamin D supplementation on the progression of sarcopenia in elderly subjects: study protocol of the SARC-PEA randomised controlled trialhttps://www.pharmaradar360.com/article/emotional-disclosure-for-alleviating-depression-anxiety-and-stress-in-women-afte-386ec9a3a7de9df0PharmaRadar360en2026-09-24T00:00:00.000ZEmotional disclosure for alleviating depression, anxiety, and stress in women after spontaneous abortion: a randomized controlled trialhttps://www.pharmaradar360.com/article/local-infiltration-versus-intramuscular-esketamine-for-procedural-pain-and-posto-2318a0d193c092bfPharmaRadar360en2026-09-24T00:00:00.000ZLocal infiltration versus intramuscular esketamine for procedural pain and postoperative PHQ-9 scores in older adults undergoing percutaneous kyphoplasty: a randomised controlled trialhttps://www.pharmaradar360.com/article/comprehensive-evaluation-of-plasma-proteomics-platforms-toward-practical-applica-e7db85d32b44d1b4PharmaRadar360en2026-09-24T00:00:00.000ZComprehensive evaluation of plasma proteomics platforms toward practical applications using accessible mass spectrometry instrumentationhttps://www.pharmaradar360.com/article/clinical-characteristics-and-outcomes-of-hypertrophic-cardiomyopathy-associated-e0f6f3c7bfda81ebPharmaRadar360en2026-09-24T00:00:00.000ZClinical Characteristics and Outcomes of Hypertrophic Cardiomyopathy Associated With Thin Filament Variants: Insights From the SHaRe Registryhttps://www.pharmaradar360.com/article/multi-criteria-decision-analysis-of-dendrimer-applications-in-drug-delivery-syst-041e66390a001be0PharmaRadar360en2026-09-24T00:00:00.000ZMulti-criteria decision analysis of dendrimer applications in drug delivery systemshttps://www.pharmaradar360.com/article/heterogeneity-of-breast-and-nodal-response-to-neoadjuvant-pembrolizumab-based-ch-f56993f250266eb1PharmaRadar360en2026-09-24T00:00:00.000ZHeterogeneity of breast and nodal response to neoadjuvant pembrolizumab‐based chemoimmunotherapy in early triple‐negative breast cancer and its clinical significancehttps://www.pharmaradar360.com/article/triage-administration-of-ondansetron-for-gastroenteritis-in-children-8cc45fd4d1f1be8dPharmaRadar360en2026-09-24T00:00:00.000ZTriage Administration of Ondansetron for Gastroenteritis in Childrenhttps://www.pharmaradar360.com/article/letter-to-the-editor-an-acceptance-based-healthy-lifestyle-programme-for-communi-9e8b88965342ff19PharmaRadar360en2026-09-24T00:00:00.000ZLetter to the Editor: “An acceptance-based healthy lifestyle programme for community-dwelling patients with pneumoconiosis: A waitlist pilot randomised controlled trial”https://www.pharmaradar360.com/article/the-molecular-metabolic-and-clinical-aspects-of-human-selenoproteins-a-narrative-9fed693ac9ae7fc1PharmaRadar360en2026-09-24T00:00:00.000ZThe molecular, metabolic, and clinical aspects of human selenoproteins: a narrative review of the last ten yearshttps://www.pharmaradar360.com/article/establishing-the-value-of-call-handling-metrics-in-a-united-kingdom-poisons-info-96d501ba8dbd4d6cPharmaRadar360en2026-09-24T00:00:00.000ZEstablishing the value of call-handling metrics in a United Kingdom Poisons Information Centrehttps://www.pharmaradar360.com/article/surgical-telementoring-platforms-for-clinical-care-and-training-a-systematic-rev-417edb1bfd1a54b1PharmaRadar360en2026-09-24T00:00:00.000ZSurgical telementoring platforms for clinical care and training: a systematic reviewhttps://www.pharmaradar360.com/article/psychosocial-and-clinical-factors-associated-with-diabetes-self-management-in-ty-ff48bf860447a18bPharmaRadar360en2026-09-24T00:00:00.000ZPsychosocial and clinical factors associated with diabetes self-management in type 2 diabeteshttps://www.pharmaradar360.com/article/sustained-intravitreal-delivery-of-triamcinolone-acetonide-via-in-situ-forming-l-5c18ed713309c5c3PharmaRadar360en2026-09-24T00:00:00.000ZSustained intravitreal delivery of triamcinolone acetonide via in situ forming lipid liquid crystals: in-vitro and in-vivo evaluationshttps://www.pharmaradar360.com/article/targeting-exosome-conjugated-with-cardiac-homing-peptide-alleviates-myocardial-i-da0e401a6a4a33e0PharmaRadar360en2026-09-24T00:00:00.000ZTargeting exosome conjugated with cardiac homing peptide alleviates myocardial infarction by delivering miRNAshttps://www.pharmaradar360.com/article/how-repeal-of-the-ntap-alternative-pathway-will-impact-u-s-clinical-ai-innovatio-73bf9e1dbd1e638fPharmaRadar360en2026-09-24T00:00:00.000ZHow Repeal of the NTAP Alternative Pathway will Impact U.S. Clinical AI Innovationhttps://www.pharmaradar360.com/article/from-technical-performance-to-clinical-readiness-a-phase-based-framework-for-evi-2073a706a466abd2PharmaRadar360en2026-09-24T00:00:00.000ZFrom Technical Performance to Clinical Readiness: A Phase-Based Framework for Evidence Standards in Clinical Artificial Intelligencehttps://www.pharmaradar360.com/article/new-approach-methodologies-drug-screening-platform-to-identify-antifibrotic-comp-bc05f6f071d85d54PharmaRadar360en2026-09-24T00:00:00.000ZNew approach methodologies: drug screening platform to identify antifibrotic compoundshttps://www.pharmaradar360.com/article/waterless-mof-des-eutectogels-with-adaptive-viscoelasticity-for-dual-hydrophilic-d2680ba1651e875dPharmaRadar360en2026-09-24T00:00:00.000ZWaterless MOF−DES Eutectogels with Adaptive Viscoelasticity for Dual Hydrophilic−Hydrophobic Drug Deliveryhttps://www.pharmaradar360.com/article/analyzing-and-redesigning-deployment-pathways-for-internally-developed-artificia-af509b768608b3f5PharmaRadar360en2026-09-24T00:00:00.000ZAnalyzing and redesigning deployment pathways for internally developed artificial intelligence tools in clinical education and health researchhttps://www.pharmaradar360.com/article/response-to-correspondence-pharmacogenomics-and-digital-adherence-tools-a-commen-ec0f525822d42de2PharmaRadar360en2026-09-24T00:00:00.000ZResponse to Correspondence: Pharmacogenomics and Digital Adherence Tools—A Commentary on Vahdati et al.https://www.pharmaradar360.com/article/supramolecular-salicylic-acid-chemical-peeling-combined-with-supramolecular-acti-b0f0423ae96908ddPharmaRadar360en2026-09-24T00:00:00.000ZSupramolecular Salicylic Acid Chemical Peeling Combined with Supramolecular Active Zinc for Malassezia Folliculitis: Efficacy and Safety from a Multicenter, Single-Arm Trialhttps://www.pharmaradar360.com/article/the-effects-of-coenzyme-q10-supplementation-on-exercise-induced-oxidative-stress-93afc53a8c0ba492PharmaRadar360en2026-09-24T00:00:00.000ZThe effects of coenzyme Q10 supplementation on exercise-induced oxidative stress and related physiological outcomes in athletes: a systematic review and meta-analysishttps://www.pharmaradar360.com/article/integrating-q-rung-picture-fuzzy-hypersoft-sets-with-aczel-alsina-operators-for-5f96258fcdd82d41PharmaRadar360en2026-09-24T00:00:00.000ZIntegrating q-rung picture fuzzy hypersoft sets with Aczel–Alsina operators for pharmaceutical supply chain managementhttps://www.pharmaradar360.com/article/staged-radiotherapy-for-symptomatic-unresectable-giant-hepatic-hemangiomas-with-748970dca67acc07PharmaRadar360en2026-09-24T00:00:00.000ZStaged radiotherapy for symptomatic unresectable giant hepatic hemangiomas with diffuse bilobar involvementhttps://www.pharmaradar360.com/article/establishing-antidiabetic-potential-of-navayasa-churnam-phyto-metabolomics-syste-c0392b5a87139d5dPharmaRadar360en2026-09-24T00:00:00.000ZEstablishing Antidiabetic Potential of Navayasa Churnam: Phyto-Metabolomics, Systems Pharmacology, In Vitro, In Vivo, and In Silico Studieshttps://www.pharmaradar360.com/article/human-neuroangiostrongyliasis-caused-by-angiostrongylus-cantonensis-in-northern-e5359583bc4dbfd4PharmaRadar360en2026-09-24T00:00:00.000ZHuman Neuroangiostrongyliasis Caused by Angiostrongylus cantonensis in Northern Vietnam: a Clinical–Epidemiological Case Series of Eosinophilic Response and Disease Manifestationshttps://www.pharmaradar360.com/article/clinical-predictors-of-at-risk-mental-states-in-general-adolescent-population-a-ca29d77470e7ce30PharmaRadar360en2026-09-24T00:00:00.000ZClinical predictors of at-risk mental states in general adolescent population: a 2-year follow-up studyhttps://www.pharmaradar360.com/article/subsequent-depression-in-patients-with-lip-and-head-and-neck-cancer-a-population-d779f0bbe3d24fa6PharmaRadar360en2026-09-24T00:00:00.000ZSubsequent depression in patients with lip and head and neck cancer: a population-based primary care analysishttps://www.pharmaradar360.com/article/correction-to-age-specific-patterns-of-lymph-node-involvement-in-elderly-patient-0db7585dd0d8bb83PharmaRadar360en2026-09-24T00:00:00.000ZCorrection to: Age-specific patterns of lymph node involvement in elderly patients with oral squamous cell carcinoma: a retrospective cohort studyhttps://www.pharmaradar360.com/article/gnal-associated-dystonia-clinical-spectrum-genetic-features-and-genotype-phenoty-89faae5b45271657PharmaRadar360en2026-09-24T00:00:00.000ZGNAL-associated dystonia: clinical spectrum, genetic features, and genotype–phenotype correlationshttps://www.pharmaradar360.com/article/letter-to-the-editor-on-clinical-and-logistical-determinants-of-operative-timing-ec647449118c39c7PharmaRadar360en2026-09-24T00:00:00.000ZLetter to the editor on: “Clinical and logistical determinants of operative timing, surgical approach, and admission in pediatric supracondylar humerus fractures”https://www.pharmaradar360.com/article/correction-to-an-excitation-customized-ict-type-turn-on-probe-for-visualization-e2c8a53da25d0c12PharmaRadar360en2026-09-24T00:00:00.000ZCorrection to: An excitation‑customized ICT‑type turn‑on probe for visualization of cysteine fluctuation in diverse drug‑induced ferroptosis pathwayshttps://www.pharmaradar360.com/article/updated-estimates-of-agreement-between-dispensed-medications-and-forensic-toxico-518bf5af11781f67PharmaRadar360en2026-09-24T00:00:00.000ZUpdated Estimates of Agreement Between Dispensed Medications and Forensic Toxicology in Swedenhttps://www.pharmaradar360.com/article/clinical-management-and-outcomes-of-neonatal-rhinitis-nasal-obstruction-a-scopin-8975fc8cab937599PharmaRadar360en2026-09-24T00:00:00.000ZClinical Management and Outcomes of Neonatal Rhinitis Nasal Obstruction: A Scoping Reviewhttps://www.pharmaradar360.com/article/treatment-duration-and-clinical-response-patterns-of-laryngopharyngeal-reflux-di-94bf8b18875eb65bPharmaRadar360en2026-09-24T00:00:00.000ZTreatment Duration and Clinical Response Patterns of Laryngopharyngeal Reflux Diseasehttps://www.pharmaradar360.com/article/scp-expression-of-concern-scp-randomized-controlled-trial-comparing-ondansetron-aa25d492a6d17cf4PharmaRadar360en2026-09-24T00:00:00.000Z<scp>EXPRESSION OF CONCERN</scp> : Randomized controlled trial comparing ondansetron and placebo for the reduction of spinal anesthesia‐induced hypotension during elective cesarean delivery in Egypthttps://www.pharmaradar360.com/article/virtual-reality-for-anxiety-and-pain-management-in-lower-limb-orthopedic-surgery-8580b8bb44e53af4PharmaRadar360en2026-09-24T00:00:00.000ZVirtual Reality for Anxiety and Pain Management in Lower Limb Orthopedic Surgery Under Spinal Anesthesia: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/laparoscopic-splenectomy-for-a-completely-infarcted-wandering-spleen-after-prolo-e4accf4b5864dd95PharmaRadar360en2026-09-24T00:00:00.000ZLaparoscopic Splenectomy for a Completely Infarcted Wandering Spleen After Prolonged Positional Abdominal Pain: A Case Report and Focused Literature Reviewhttps://www.pharmaradar360.com/article/scp-igg4-scp-to-scp-igg-scp-ratio-and-orbital-involvement-predict-clinical-respo-4f3b8f715383dd93PharmaRadar360en2026-09-24T00:00:00.000Z<scp>IgG4</scp> ‐to‐ <scp>IgG</scp> Ratio and Orbital Involvement Predict Clinical Response to B Cell Depletion in <scp>IgG4</scp> ‐Related Diseasehttps://www.pharmaradar360.com/article/nct07839767-treatment-selection-by-3d-bioprinting-liver-model-to-prevent-liver-c-73ca2158e5a1d5d9PharmaRadar360en2026-09-24T00:00:00.000ZNCT07839767: Treatment Selection by 3D Bioprinting Liver Model to Prevent Liver Cancer Recurrencehttps://www.pharmaradar360.com/article/nct07839676-a-prospective-study-of-concurrent-hyperthermia-chemotherapy-and-radi-bcfddab6e768c51ePharmaRadar360en2026-09-24T00:00:00.000ZNCT07839676: A Prospective Study of Concurrent Hyperthermia, Chemotherapy and Radiotherapy in Borderline and Locally Advanced Pancreatic Cancer (PANHEAT)https://www.pharmaradar360.com/article/nct07839429-effect-of-mhealth-intervention-on-oral-health-related-quality-of-lif-03ae595228cb3fbfPharmaRadar360en2026-09-24T00:00:00.000ZNCT07839429: Effect of mHealth Intervention on Oral Health-Related Quality of Life Among Adult Patients With Chronic Systemic Diseaseshttps://www.pharmaradar360.com/article/nct07839390-determination-of-the-best-therapeutic-strategy-interventional-with-b-7c88aba6b78c8f50PharmaRadar360en2026-09-24T00:00:00.000ZNCT07839390: Determination of the Best Therapeutic Strategy, Interventional With Best Medical Management (BMM) Versus BMM Alone, for Patients With Symptomatic Moderate <70% Atherosclerotic Carotid Artery Stenosis: the SIMCA Multicenter Randomized Trialhttps://www.pharmaradar360.com/article/nct07839143-a-prospective-multicenter-randomized-parallel-controlled-superiority-835dc5046489ff3dPharmaRadar360en2026-09-24T00:00:00.000ZNCT07839143: A Prospective, Multicenter, Randomized, Parallel-controlled, Superiority Clinical Trial Evaluating the Safety and Efficacy of Single-use Peripheral Intravascular Shock Wave Catheters Combined With Intravascular Shock Wave Therapy Devices for Peripheral Artery Calcified Lesions.https://www.pharmaradar360.com/article/nct07838792-theory-guided-socratic-ai-scaffolding-for-clinical-reasoning-in-nurs-46fa6ed30d0194eePharmaRadar360en2026-09-24T00:00:00.000ZNCT07838792: Theory-Guided Socratic AI Scaffolding for Clinical Reasoning in Nursing Studentshttps://www.pharmaradar360.com/article/nct07838519-personalizing-veterans-lung-cancer-screening-and-diagnosis-b91b2ffab0a2d9e2PharmaRadar360en2026-09-24T00:00:00.000ZNCT07838519: Personalizing Veterans' Lung Cancer Screening and Diagnosishttps://www.pharmaradar360.com/article/nct07838415-multimodalomics-based-construction-of-spatiotemporal-characteristics-5670e10fd7be4982PharmaRadar360en2026-09-24T00:00:00.000ZNCT07838415: Multimodalomics-based Construction of Spatiotemporal Characteristics of Dynamic Liver Cancer Microenvironment to Characterize the Clinical Application of Immune Mechanisms in Liver Cancerhttps://www.pharmaradar360.com/article/nct07838389-evaluation-of-donor-derived-b-cell-infusions-in-patients-with-amyotr-6d8c441a36cb372aPharmaRadar360en2026-09-24T00:00:00.000ZNCT07838389: Evaluation of Donor-Derived B Cell Infusions in Patients With Amyotrophic Lateral Sclerosis (ALS)https://www.pharmaradar360.com/article/nct07837960-exploration-of-diagnosis-etiology-and-prognosis-prediction-of-cracke-9986ebb45114f2e6PharmaRadar360en2026-09-24T00:00:00.000ZNCT07837960: Exploration of Diagnosis, Etiology, and Prognosis Prediction of Cracked Teeth in Young Adultshttps://www.pharmaradar360.com/article/nct07837921-post-market-clinical-follow-up-to-assess-the-portable-nitric-oxide-g-9f2721f8484594f7PharmaRadar360en2026-09-24T00:00:00.000ZNCT07837921: Post Market Clinical Follow-up to Assess the Portable Nitric Oxide Generation and Delivery System (INOwill N200) for the Treatment of Neonatal Hypoxic Respiratory Failure Complicated by Pulmonary Hypertensionhttps://www.pharmaradar360.com/article/nct07835100-probiotics-for-sustained-health-0bd133d29e3e07c1PharmaRadar360en2026-09-24T00:00:00.000ZNCT07835100: Probiotics for Sustained Healthhttps://www.pharmaradar360.com/article/nct07829224-effects-of-green-tea-mouthwash-on-halitosis-periodontal-health-and-s-93034438aa1638bbPharmaRadar360en2026-09-24T00:00:00.000ZNCT07829224: Effects of Green Tea Mouthwash on Halitosis, Periodontal Health, and Stress in Orthodontic Patientshttps://www.pharmaradar360.com/article/nct07804719-possible-sarcopenia-sarcopenia-and-functional-status-in-patients-wit-c03b1338aa2a5c39PharmaRadar360en2026-09-24T00:00:00.000ZNCT07804719: Possible Sarcopenia, Sarcopenia, and Functional Status in Patients With Primary Sjögren's Syndrome